John Renger - Mar 9, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Mar 9, 2022
Transactions value $: -$895,000
Form type: 4
Date filed: 3/11/2022, 03:08 PM
Previous filing: Mar 4, 2022
Next filing: Mar 18, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$105K	+30K	+1515.15%	$3.50^*	32K	Mar 9, 2022	Direct	F1
transaction	CERE	Common Stock	Sale	-$650K	-20K	-62.54%	$32.50	12K	Mar 9, 2022	Direct	F1
transaction	CERE	Common Stock	Sale	-$350K	-10K	-83.47%	$35.00	1.98K	Mar 9, 2022	Direct	F1

Showing 1 to 3 of 3 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-30K	-9.35%	$0.00	291K	Mar 9, 2022	Common Stock	30K	$3.50	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.